DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ZONISAMIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ZOLPIDEM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ZIPRASIDONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN STRONG)) SUBSTRATE-OF (CYP1A2) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ZILEUTON :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ZALEPLON :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG) (CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ZAFIRLUKAST :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG) (CYP2C19 UNKNOWN STRONG) (CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF (CYP2C9 CYP2C19 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME VORICONAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME VINCRISTINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME VINBLASTINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (UNKNOWN INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 IRREVERSIBLE MODERATE) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME VERAPAMIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN WEAK)) SUBSTRATE-OF (CYP2C9 CYP2C19 CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME VENLAFAXINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME VARDENAFIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME VALSARTAN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME VALDECOXIB :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 MICOMPLEX STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TROLEANDOMYCIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C8 UNKNOWN UNKNOWN)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TRIMETHOPRIM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TRIAZOLAM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TRAZODONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TRAMADOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TORSEMIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C19 UNKNOWN WEAK)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TOPIRAMATE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TOLTERODINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TOLBUTAMIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TIMOLOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C19 UNKNOWN MODERATE)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TICLOPIDINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 COMPETITIVE STRONG)) SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME THIORIDAZINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME THEOPHYLLINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TESTOSTERONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 VERY_HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TERFENADINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TERBINAFINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TENIPOSIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP2C9 CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TAMOXIFEN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TADALAFIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 HIGH) NARROW-THER-INDEX YES INDUCES NIL INHIBITS ((P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TACROLIMUS :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP1A2 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN STRONG)) SUBSTRATE-OF (CYP1A2) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME TACRINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SULPHAPHENAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SULFINPYRAZONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SULFAMETHOXAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SULFAMETHIZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SUFENTANIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SIROLIMUS :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 VERY_HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SIMVASTATIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (UNKNOWN INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SILDENAFIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SIBUTRAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN WEAK) (CYP3A4 UNKNOWN WEAK)) SUBSTRATE-OF (CYP2C19 CYP2C9 CYP2B6 CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SERTRALINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SELEGILINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 VERY_HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME SAQUINAVIR :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C8 UNKNOWN UNKNOWN)) SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ROSIGLITAZONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ROPINIROLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN WEAK)) SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ROFECOXIB :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME RIVASTIGMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 LOW) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME RITONAVIR :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN WEAK)) SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME RISPERIDONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP1A2 UNKNOWN) (CYP2C8 UNKNOWN) (CYP2C9 UNKNOWN) (CYP2C19 UNKNOWN) (CYP2D6 UNKNOWN) (CYP3A4 UNKNOWN) (P-GLYCOPROTEIN UNKNOWN)) INHIBITS NIL SUBSTRATE-OF (P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME RIFAMPIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP3A4 UNKNOWN)) INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME RIFABUTIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME REPAGLINIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C19) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME RABEPRAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME QUINUPRISTIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (UNKNOWN LOW) NARROW-THER-INDEX YES INDUCES NIL INHIBITS ((CYP2D6 COMPETITIVE STRONG) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME QUINIDINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 COMPETITIVE STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME QUINACRINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME QUETIAPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C19 CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PROPRANOLOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN UNKNOWN) (CYP2D6 UNKNOWN STRONG)) SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PROPOXYPHENE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 HIGH) NARROW-THER-INDEX YES INDUCES NIL INHIBITS ((CYP2D6 COMPETITIVE STRONG) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PROPAFENONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN STRONG)) SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PROMETHAZINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C19) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PROGUANIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES ((CYP3A4 UNKNOWN)) INHIBITS NIL SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PRIMIDONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PREDNISONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PREDNISOLONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PLICAMYCIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PIROXICAM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C8 UNKNOWN UNKNOWN)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PIOGLITAZONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PIMOZIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2C9 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES ((CYP2C9 MODERATE) (CYP2C19 UNKNOWN) (CYP3A4 MODERATE) (UGT MODERATE) (CYP2B6 MODERATE) (CYP1A2 MODERATE)) INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP2C19) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PHENYTOIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2C9 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES ((CYP1A2 MODERATE) (CYP2B6 MODERATE) (CYP2C9 MODERATE) (CYP3A4 MODERATE) (UGT MODERATE)) INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP2B6 CYP2C19 CYP2E1) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PHENOBARBITOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 COMPETITIVE STRONG)) SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PERPHENAZINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PERHEXILINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C19) SIDE-EFFECTS NIL INDICATIONS NIL FORM INHALATION DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PENTAMIDINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 COMPETITIVE STRONG)) SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS (ANTIDEPRESSANT) FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PAROXETINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C19 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PANTOPRAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C8 CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME PACLITAXEL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME OXYCODONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP3A4 UNKNOWN)) INHIBITS ((CYP2C19 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME OXYCARBAZEPINE :END DRUG PRODRUG YES CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP3A4 WEAK) (UGT WEAK)) INHIBITS ((CYP2C19 UNKNOWN WEAK)) SUBSTRATE-OF (UGT) SIDE-EFFECTS NIL INDICATIONS (AED) FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME OXCARBAZEPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP2D6 CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ONDANSETRON :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C19 UNKNOWN STRONG) (CYP3A4 COMPETITIVE STRONG)) SUBSTRATE-OF (CYP2C19 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME OMEPRAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP2C19) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME OLANZAPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NORTRIPTYLINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN WEAK)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NORFLOXACIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 VERY_HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NISOLDIPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 VERY_HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NIMODIPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((P-GLYCOPROTEIN UNKNOWN WEAK)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NIFEDIPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 UNKNOWN WEAK) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NICARDIPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP3A4 UNKNOWN)) INHIBITS NIL SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NEVIRAPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NELFINAVIR :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 COMPETITIVE STRONG)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NEFAZODONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN UNKNOWN)) SUBSTRATE-OF (CYP2C9 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NATEGLINIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NAPROXEN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP3A4 UNKNOWN)) INHIBITS NIL SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME NAFCILLIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MORPHINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MONTELUKAST :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP3A4 UNKNOWN)) INHIBITS ((CYP2C9 UNKNOWN WEAK) (CYP2C19 UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MODAFINIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MITOMYCIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP2D6 CYP3A4 UGT) SIDE-EFFECTS NIL INDICATIONS (ANTIDEPRESSANT) FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MIRTAZAPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 MICOMPLEX UNKNOWN) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MIFEPRISTONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 COMPETITIVE WEAK)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MIDAZOLAM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN UNKNOWN) (CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MICONAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN STRONG)) SUBSTRATE-OF (CYP1A2 CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MEXILETINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME METRONIDAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME METOPROLOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME METHYLPREDNISOLONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME METHAMPHETAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME METHADONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MELOXICAM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME MAPROTILINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 VERY_HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 UNKNOWN WEAK)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LOVASTATIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (UNKNOWN INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LOSARTAN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6 CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LORATADINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LOPINAVIR :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LOPERAMIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LIDOCAINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LEVOMETHADYL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LEFLUNOMIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C19 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LANSOPRAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY UGT PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (UGT) SIDE-EFFECTS NIL INDICATIONS (AED) FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME LAMOTRIGINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C8 UNKNOWN UNKNOWN) (CYP3A4 IRREVERSIBLE STRONG) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME KETOCONAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 UNKNOWN STRONG) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ITRACONAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ISRADIPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN STRONG) (CYP2C19 UNKNOWN STRONG) (CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ISONIAZID :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME IRINOTECAN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME IRBESARTAN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME INDOMETHACIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME INDINAVIR :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP2C19 CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME IMIPRAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG) (CYP2D6 UNKNOWN STRONG) (CYP3A4 UNKNOWN MODERATE)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME IMATINIB :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME IFOSFAMIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME IBUPROFEN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP2C9 UNKNOWN) (CYP2C19 UNKNOWN) (CYP3A4 UNKNOWN) (P-GLYCOPROTEIN UNKNOWN)) INHIBITS NIL SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME HYPERFORIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME HYDROCODONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN STRONG)) SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME HALOPERIDOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP3A4 UNKNOWN)) INHIBITS NIL SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME GRISEOFULVIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME GLYBURIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME GLIPIZIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME GLIMEPIRIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 IRREVERSIBLE UNKNOWN)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME GESTODENE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C8 UNKNOWN UNKNOWN) (CYP2C9 UNKNOWN STRONG) (CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME GEMFIBROZIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN WEAK)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME GEFITINIB :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (UGT CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME GALANTAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FROVATRIPTAN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN STRONG) (CYP2C9 UNKNOWN UNKNOWN) (CYP2C9 UNKNOWN WEAK) (CYP2C19 UNKNOWN STRONG) (CYP3A4 COMPETITIVE STRONG)) SUBSTRATE-OF (CYP1A2 CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FLUVOXAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN WEAK)) SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FLUVASTATIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FLURBIPROFEN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN MODERATE) (CYP2C19 UNKNOWN MODERATE) (CYP2D6 COMPETITIVE STRONG) (CYP3A4 IRREVERSIBLE MODERATE)) SUBSTRATE-OF (CYP2C19 CYP2D6) SIDE-EFFECTS NIL INDICATIONS (ANTIDEPRESSANT) FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FLUOXETINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FLUOROURACIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG) (CYP2C19 UNKNOWN STRONG) (CYP3A4 COMPETITIVE STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FLUCONAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS ((CYP2D6 COMPETITIVE STRONG)) SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FLECAINIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FINASTERIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FEXOFENADINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FENTANYL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FELODIPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C19 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME FELBAMATE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ETOPOSIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG NIL)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ETHANOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (UNKNOWN HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ESTRADIOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN WEAK)) SUBSTRATE-OF (CYP2C19 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ESCITALOPRAM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 MICOMPLEX MODERATE) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ERYTHROMYCIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 VERY_HIGH) NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ERGOTAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME EPLERENONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ENOXACIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ENCAINIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ELETRIPTAN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP3A4 UNKNOWN)) INHIBITS ((CYP2C9 UNKNOWN STRONG) (CYP2C19 UNKNOWN STRONG)) SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME EFAVIRENZ :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DUTASTERIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DROPERIDOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DRONABINOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DOXORUBICIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP2C19 CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DOXEPIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6 CYP3A4 UGT) SIDE-EFFECTS NIL INDICATIONS (DEMENTIA) FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DONEPEZIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DOFETILIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DOCETAXEL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN WEAK)) SUBSTRATE-OF (CYP1A2 CYP2D6) SIDE-EFFECTS NIL INDICATIONS (ANTIDEPRESSANT) FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DULOXETINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DISULFIRAM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 LOW) NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DISOPYRAMIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DIPHENHYDRAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (UNKNOWN INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 MICOMPLEX MODERATE) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DILTIAZEM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DIHYDROCODEINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM RENAL PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DIGOXIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DICLOFENAC :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C19 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DIAZEPAM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DEXTROMETHORPHAN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 LOW) NARROW-THER-INDEX NO INDUCES ((CYP3A4 UNKNOWN)) INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DEXAMETHASONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS ((CYP2D6 COMPETITIVE STRONG)) SUBSTRATE-OF (CYP2C19 CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DESIPRAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN STRONG) (CYP2C19 UNKNOWN STRONG) (CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DELAVIRDINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DEBRISOQUIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DAUNORUBICIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 LOW) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DAPSONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME DANAZOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX YES INDUCES NIL INHIBITS ((CYP3A4 COMPETITIVE STRONG) (P-GLYCOPROTEIN UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CYCLOSPORINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN UNKNOWN)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME COTRIMOXAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME COLCHICINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CODEINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP2C19) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CLOZAPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C8 UNKNOWN UNKNOWN)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CLOTRIMAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN WEAK)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CLOPIDOGREL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP2C19 CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CLOMIPRAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 MICOMPLEX STRONG) (P-GLYCOPROTEIN UNKNOWN WEAK)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CLARITHROMYCIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP2D6 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN WEAK)) SUBSTRATE-OF (CYP2C19 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CITALOPRAM :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CISAPRIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CIPROFLOXACIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM RENAL PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN WEAK) (CYP2C19 UNKNOWN STRONG) (CYP2D6 UNKNOWN WEAK)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CIMETIDINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 UNKNOWN WEAK)) SUBSTRATE-OF (CYP3A4 CYP2C19) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CILOSTAZOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CHLORPROPAMIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 COMPETITIVE STRONG)) SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CHLORPROMAZINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN STRONG)) SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CHLORPHENIRAMINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CHLOROQUINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CEVIMELINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CELECOXIB :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (UNKNOWN INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6 CYP2C9) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CARVEDILOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2C19) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CARISOPRODOL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY CYP3A4 PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX YES INDUCES ((CYP1A2 MODERATE) (CYP2B6 MODERATE) (CYP2C8 UNKNOWN) (CYP2C9 MODERATE) (CYP2C19 WEAK) (CYP3A4 MODERATE) (UGT MODERATE)) INHIBITS ((CYP2C19 UNKNOWN WEAK)) SUBSTRATE-OF (CYP1A2 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CARBAMAZEPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME CAFFEINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 VERY_HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME BUSPIRONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP2D6 UNKNOWN STRONG)) SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME BUPROPION :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME BUPRENORPHINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME BUPIVACAINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME BUDESONIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME BROMOCRIPTINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP2C9 UNKNOWN) (CYP3A4 UNKNOWN)) INHIBITS NIL SUBSTRATE-OF (CYP2C9 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME BOSENTAN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME BEXAROTENE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME BEPRIDIL :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 UNKNOWN WEAK)) SUBSTRATE-OF (CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ATORVASTATIN :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ATOMOXETINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP1A2 UNKNOWN UNKNOWN) (CYP2C9 UNKNOWN UNKNOWN) (CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ATAZANAVIR :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 VERY_HIGH) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ASTEMIZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ARIPIPRAZOLE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP2C9 UNKNOWN)) INHIBITS ((CYP3A4 UNKNOWN MODERATE)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME APREPITANT :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 INTERMEDIATE) NARROW-THER-INDEX NO INDUCES NIL INHIBITS ((CYP3A4 UNKNOWN STRONG)) SUBSTRATE-OF (CYP2C9 CYP2D6 CYP3A4 P-GLYCOPROTEIN) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME AMPRENAVIR :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (CYP3A4 LOW) NARROW-THER-INDEX NO INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME AMLODIPINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP1A2 CYP2D6 CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME AMITRIPTYLINE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS (UNKNOWN INTERMEDIATE) NARROW-THER-INDEX YES INDUCES NIL INHIBITS ((CYP2C9 UNKNOWN MODERATE) (CYP2D6 UNKNOWN MODERATE) (P-GLYCOPROTEIN UNKNOWN STRONG) (CYP3A4 UNKNOWN UNKNOWN)) SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME AMIODARONE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX NO INDUCES ((CYP2C9 UNKNOWN) (CYP2C9 UNKNOWN) (CYP3A4 UNKNOWN)) INHIBITS NIL SUBSTRATE-OF NIL SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME AMINOGLUTETHIMIDE :END DRUG PRODRUG NO CONTRAINDICATION NIL MAJOR-PATHWAY NIL PRIMARY-CLEARANCE-MECHANISM METABOLIC PRIMARY-FIRST-PASS-ENZYME NIL LEVEL-OF-FIRST-PASS UNKNOWN NARROW-THER-INDEX YES INDUCES NIL INHIBITS NIL SUBSTRATE-OF (CYP3A4) SIDE-EFFECTS NIL INDICATIONS NIL FORM NIL DOSAGE NIL INGREDIENT NIL DRUG-CLASS NIL GENERIC-NAME ALFENTANIL :END